Related Experiment Video

Updated: Jun 11, 2025

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells
11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.4K

Investigating the role of HSP90 in cancer cell phenotypic plasticity

Vincent Sollars1, Alexandria Chapman1, Nicole R Liang1

  • 1Department of Biomedical Sciences at Joan C. Edwards School of Medicine at Marshall University, USA.

Journal of Breast Cancer Research
|October 4, 2024
PubMed

Insights

Heat shock protein 90 (HSP90) inhibition reduces cancer cell adaptability, enhancing chemotherapy effectiveness. Targeting HSP90 may be a novel strategy to overcome multi-drug resistance and improve cancer treatment outcomes.

Area of Science:

  • Cancer Biology
  • Epigenetics
  • Chemotherapy Resistance

Background:

  • Epigenetic gene regulation is crucial in cancer progression and adaptation to chemotherapy.
  • Heat shock protein 90 (HSP90) plays a key role in epigenetic regulation, histone acetylation, and phenotypic plasticity.
  • HSP90 is overexpressed in various cancers, correlating with poor prognosis.

Purpose of the Study:

  • To investigate the role of HSP90 in the phenotypic plasticity of cancer cells, specifically concerning multi-drug resistance and epithelial-to-mesenchymal transition.
  • To test the hypothesis that HSP90 inhibition reduces cancer cell plasticity, increasing susceptibility to chemotherapeutic agents.

Main Methods:

  • Utilized an A549 lung cancer model.
  • Investigated the impact of HSP90 on epigenetic gene regulation, histone acetylation, and phenotypic plasticity.
  • Assessed the effects of HSP90 inhibition on multi-drug resistance and epithelial-to-mesenchymal transition phenotypes.

Main Results:

  • Confirmed HSP90's critical role in epigenetic gene regulation and phenotypic plasticity.
  • Demonstrated that HSP90 inhibition leads to decreased phenotypic plasticity in lung cancer cells.
  • Showed that reduced plasticity enhances cancer cell susceptibility to chemotherapeutic interventions.

Conclusions:

  • HSP90 inhibition is a promising strategy to lower cancer cell phenotypic plasticity.
  • Targeting HSP90 can potentially overcome multi-drug resistance and improve chemotherapy efficacy.
  • Understanding HSP90's role in tumor evolution is vital for developing more effective cancer therapies.
Keywords:
CancerCellular StressEpidgeneticHSP90Histone AcetylationMulti-drug ResistancePhenotypic Plasticity

More Related Videos

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

14.7K
Author Spotlight: Epigenetic Modifications and Metabolic Rewiring as Targets for Cancer Therapy07:20

Author Spotlight: Epigenetic Modifications and Metabolic Rewiring as Targets for Cancer Therapy

Published on: October 18, 2024

475

Related Concept Videos

Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
4.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
4.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K